MDLN vs. RMD: Medline vs. ResMed Stock Comparison

Company Profile

Medline (MDLN) and ResMed (RMD) both belong to the Health Care Equipment & Supplies industry, though MDLN is classified under Health Care Supplies while RMD falls under Health Care Equipment.

ResMed (RMD) has been public since June 2, 1995, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. ResMed (RMD) has a non-negative beta of 0.75.

Risk-Adjusted Performance

Risk-Return Positioning

Both MDLN and RMD need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

ResMed (RMD) at 26.40% sits in the top ROE quartile, while Medline (MDLN) at 4.85% is closer to the peer norm — stronger capital efficiency for RMD.

ResMed (RMD) at 27.79% retains a top-quartile share of revenue as profit, ahead of Medline (MDLN) at 1.85%, which keeps about the industry-typical share.

ResMed (RMD) at 34.82% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: ResMed (RMD) reports revenue growth of 9.85%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Only one side can be read here: Medline (MDLN) reports EPS growth of 117.38%, ranked against its industry; ResMed (RMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

ResMed (RMD) at 2.65 keeps current ratio within its industry’s typical mid-range, while Medline (MDLN) at 4.04 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

ResMed (RMD) at 0.10 keeps leverage in the lower industry quartile, while Medline (MDLN) at 0.65 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Medline (MDLN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile ResMed (RMD) reports a yield of 1.03%, ranking against industry peers normally.

Medline (MDLN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile ResMed (RMD) reports a payout of 22.40%, ranking against industry peers normally.

Dividend Metrics

Valuation

ResMed (RMD) at 21.43 is near its industry’s usual P/E ratio, while Medline (MDLN) at 90.09 sits above its peer range — an unusually expensive price for MDLN’s trailing earnings.

Medline (MDLN) at 1.70 is priced about in line with its industry on P/S ratio, while ResMed (RMD) at 5.77 sits in the pricier quartile — RMD costs more per dollar of sales.

On P/B ratio, both Medline (MDLN) at 2.95 and ResMed (RMD) at 5.56 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics